Current landscape of personalized clinical treatments for triple-negative breast cancer
Jun Zhang(OSF HealthCare), Yiping Wu(Huazhong University of Science and Technology), Yufang Tan(Tongji Hospital), Xiaomei Zhou(Tongji Hospital), Qi Zhang(Peking University), Yu Xia(Chongqing Technology and Business University), Honghao Yu(Tongji Hospital), Yaying Du(Yale Cancer Center)
Cited by 44
Related Papers
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
|Cell|2019|326
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
|Annals of Oncology|2018|217
In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma
|Nature Biotechnology|2019|205
Early detection of lung cancer by using an autoantibody panel in Chinese population
|OncoImmunology|2017|203